The pharmacological advantages of GLP-1RAs in type 2 diabetes include correction of fasting and postprandial hyperglycemia (without increased risk of hypoglycemia due to the glucose-dependency of the insulinotropic and glucagonostatic effects of GLP-1; only operating at plasma glucose levels above 4–5 mmol/L) and weight loss. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.